Features and Benefits

• Features MiSight^® 1 day ActivControl^® Technology combined with the advanced silicone hydrogel material used in MyDay^® lenses.^†2
• ActivControl^® Technology includes vision correction zones and treatment zones to simultaneously provide clear vision and slow the progression of myopia.⁵
• ActivControl^® Technology works at any age a child starts treatment (ages 8+).^‡5,6
• 100% of children in a clinical study were successfully fit with MyDay^® MiSight^® 1 day ^§7 
• Features ActivControl^® Technology which works for nearly all children with myopia^◊ and cuts the worsening of myopia by approximately half. ^¶3,5,6
• UV blocking to help protect the eye from transmission of harmful UV radiation.^**
• Certified plastic neutral contact lens.^††8

 ActivControl^® Technology is supported by 7 years of clinical evidence^‡‡5,8 from the longest-running soft contact lens study among children.^‡‡

Product disclaimers

It is up to the individual eye care practitioner to be aware of regulatory requirements for prescribing in their country of practice, and also be aware that not all products are available in all countries.

 * Based on adherence to replacement schedule, lens handling, comfort, satisfaction, vision quality, and visual acuity findings.

† Proven to slow myopia progression in children compared to a single vision 1-day lens over a 3-year period. 

‡ As long as they remained wearing the lens as prescribed, children with myopia ages 8-15 continued to experience slowed myopia progression with MiSight^® 1 day, which shares the same ActivControl^® Technology with MyDay^® MiSight^® 1 day.

§ 100% fit acceptance with mean scores for fit acceptance (3.4/4)

◊ 90% of myopic eyes respond to treatment with MiSight^® 1 day (ages 11-15 at start of wear, n=90), which shares the same ActivControl^® Technology with MyDay^® MiSight^® 1 day.

¶ Using measured and modeled data, pooled across ages 8-17, myopia progression was slowed by an average of approximately 50% with MiSight^® 1 day, which shares the same ActivControl^® Technology with MyDay^® MiSight^® 1 day.

** Warning: UV-absorbing contact lenses are not substitutes for protective UV-absorbing eyewear, such as UV-absorbing goggles or sunglasses, because they do not completely cover the eye and surrounding area. Patients should continue to use UV-absorbing eyewear as directed.

†† Through its partnership with Plastic Bank, CooperVision offsets a portion of its plastic footprint by funding the collection and recycling of plastic waste, equivalent in weight to the plastic used in participating soft contact lens products sold in participating countries, gathered within 30 miles of oceans or waterways in countries where Plastic Bank operates. Plastic weight is based on the total weight of plastic in the lens, blister, and secondary packaging, including laminates, adhesives, and auxiliary inputs (e.g. ink). This does not include plastic used during the manufacturing process.

‡‡ MyDay^® MiSight^® 1 day contact lenses use the same ActivControl^® Technology as the original MiSight^® 1 day.

ActivControl^®, CooperVision^®, MiSight^®, and MyDay^® are registered trademarks of The Cooper Companies, Inc. and its subsidiaries.

© 2026 CooperVision.

1. CVI data on file 2025. Prospective, 1-week, double masked, randomized, bilateral crossover study with MiSight^® 1 day and MyDay^® MiSight^® 1 day. N=32 subjects aged 8-18 years.
2. Chamberlain P et al A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci. 2019;96:556-567.
3. Chamberlain P, et al. Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. OVS 2022 Mar 1;99(3):204-212.
4. Chamberlain P, et al. Eye growth and myopia progression following cessation of myopia control therapy with a dual-focus soft contact lens. OVS 2025; 102(5):353-358.
5. CVI data on file, 2025.
6. Arumugam B et al. Modelling Age Effects of Myopia Progression for the MiSight 1 day Clinical Trial. IOVS 2021;62(8):2333.
7. CVI data on file 2025. Prospective, 1-week, double masked, bilateral study with MyDay MiSight 1 day. N=32 subjects aged 8-18 years.
8. CVI data on file, 2024.